{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:16:52Z","timestamp":1740140212279,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"German Children\u2019s Cancer Foundation"},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Steirische Kinderkrebshilfe"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed magnetic resonance imaging (MRI) at the end of first-line therapy were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty patients (23.8%) had residual lesions in the tumor bed (R+\/M0), 51 (60.7%) had distant lesions (R0\/M+) and 13 (15.5%) had both (R+\/M+). Overall response to first-line therapy was minor or partial (\u2265\u200525% reduction, minor response [MR]\/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR\/PR (pptPFS: 62.5\u2005\u00b1\u20057.0%[MR\/PR] vs. 35.9\u2005\u00b1\u200512.8%[SD], P\u2005=\u2005.03; pptOS: 79.7\u2005\u00b1\u20055.9[MR\/PR] vs. 55.5\u2005\u00b1\u200513.9[SD], P\u2005=\u2005.04). Furthermore, R+\/M\u2005+\u2005was associated with a higher risk for progression (5-year pptPFS: 22.9\u2005\u00b1\u200517.9%[R+, M+] vs. 72.4\u2005\u00b1\u200512.0%[R+, M0]; P\u2005=\u2005.03). Watch-and-wait was pursued in 58 patients, while n\u2005=\u200526 received additional treatments (chemotherapy only, n\u2005=\u200519; surgery only, n\u2005=\u20052; combined, n\u2005=\u20053; valproic acid, n\u2005=\u20052), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5\u2005\u00b1\u20057.7% vs. 51.6\u2005\u00b1\u200510.7% P\u2005=\u2005.71; 5-year pptOS: 76.3\u2005\u00b1\u20056.9% vs. 69.8\u2005\u00b1\u20059.7%, P\u2005=\u2005.74). For the whole cohort, 5-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0\u2005\u00b1\u200535.4%, group-4, 52.5\u2005\u00b1\u200510.5, group-3 54.2\u2005\u00b1\u200513.8%; (P\u2005=\u2005.08).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in the case of solitary persistent medulloblastoma MRI lesions, additional therapy was not beneficial. Therefore, treatment response, extent\/kind of residual lesions and further diagnostic information need consideration for indication of additional treatments for persisting lesions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noae071","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:59:35Z","timestamp":1712242775000},"page":"1712-1722","source":"Crossref","is-referenced-by-count":0,"title":["Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-8452","authenticated-orcid":false,"given":"Denise","family":"Obrecht-Sturm","sequence":"first","affiliation":[{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Sch\u00f6mig","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-2719","authenticated-orcid":false,"given":"Martin","family":"Mynarek","sequence":"additional","affiliation":[{"name":"Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"},{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bison","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Augsburg , Augsburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department for Radiotherapy, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Pietsch","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, Brain Tumor Reference Center of the German Society for Neuropathology and Neuroanatomy (DGNN), University of Bonn, DZNE German Center for Neurodegenerative Diseases , Bonn , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5322","authenticated-orcid":false,"given":"Stefan M","family":"Pfister","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Heidelberg University Hospital , Heidelberg , Germany"},{"name":"Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK) , Heidelberg , Germany"},{"name":"Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sill","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Heidelberg University Hospital , Heidelberg , Germany"},{"name":"Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK) , Heidelberg , Germany"},{"name":"Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Sturm","sequence":"additional","affiliation":[{"name":"Pediatric Glioma Research Group, German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Department of Pediatric Hematology and Oncology, Heidelberg University Hospital , Heidelberg , Germany"},{"name":"Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[{"name":"CCU Neuropathology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg University Hospital , Heidelberg , Germany"},{"name":"Department of Neuropathology, University Heidelberg Heidelberg , Germany"},{"name":"Hopp Children\u2019s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf-Dieter","family":"Kortmann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Leipzig , Leipzig , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas U","family":"Gerber","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, University Children\u2019s Hospital Z\u00fcrich , Z\u00fcrich , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 O","family":"von Bueren","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, Obstetrics and Gynecology, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Fleischhack","sequence":"additional","affiliation":[{"name":"Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen , Essen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-1121","authenticated-orcid":false,"given":"Ulrich","family":"Sch\u00fcller","sequence":"additional","affiliation":[{"name":"Research Institute Kinderkrebs-Zentrum Hamburg , Hamburg , Germany"},{"name":"Department of Neuropathology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"},{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Nussbaumer","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Benesch","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"issue":"1","key":"2024090518440909300_CIT0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"2024090518440909300_CIT0002","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","article-title":"Childhood brain tumors: Current management, biological insights, and future directions","volume":"23","author":"Pollack","year":"2019","journal-title":"J Neurosurg Pediatr"},{"issue":"10","key":"2024090518440909300_CIT0003","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol."},{"issue":"7","key":"2024090518440909300_CIT0004","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.20.01372","article-title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: Results of an international phase III trial (SJMB03)","volume":"39","author":"Gajjar","year":"2021","journal-title":"J Clin Oncol."},{"issue":"34","key":"2024090518440909300_CIT0005","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","article-title":"Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters","volume":"34","author":"Bueren","year":"2016","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024090518440909300_CIT0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: The current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2024090518440909300_CIT0007","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(18)30532-1","article-title":"Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT\/non-SHH medulloblastoma: A retrospective, molecular analysis of the HIT-SIOP PNET 4 trial","volume":"19","author":"Goschzik","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7697","key":"2024090518440909300_CIT0008","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"7","key":"2024090518440909300_CIT0009","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","article-title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study","volume":"18","author":"Schwalbe","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7663","key":"2024090518440909300_CIT0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature."},{"issue":"6","key":"2024090518440909300_CIT0011","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"issue":"33","key":"2024090518440909300_CIT0012","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1200\/JCO.2010.30.2299","article-title":"Survival and prognostic factors of early childhood medulloblastoma: An international meta-analysis","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024090518440909300_CIT0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1470-2045(15)00581-1","article-title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: A retrospective integrated clinical and molecular analysis","volume":"17","author":"Thompson","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"2024090518440909300_CIT0014","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/neuros\/nyy095","article-title":"Reoperation for medulloblastoma prior to adjuvant therapy","volume":"84","author":"Patel","year":"2019","journal-title":"Neurosurgery."},{"issue":"3","key":"2024090518440909300_CIT0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-018-2906-5","article-title":"The clinical importance of medulloblastoma extent of resection: A systematic review","volume":"139","author":"Thompson","year":"2018","journal-title":"J Neurooncol."},{"issue":"1","key":"2024090518440909300_CIT0016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MPH.0b013e3182843b40","article-title":"Chronic residual lesions in metastatic medulloblastoma patients","volume":"36","author":"Fried","year":"2014","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"2024090518440909300_CIT0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2021.12.032","article-title":"Refining M1 stage in medulloblastoma: Criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial","volume":"164","author":"Hagel","year":"2022","journal-title":"Eur J Cancer."},{"issue":"6","key":"2024090518440909300_CIT0018","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1148\/93.6.1351","article-title":"An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas","volume":"93","author":"Chang","year":"1969","journal-title":"Radiology."},{"issue":"6","key":"2024090518440909300_CIT0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/nor025","article-title":"Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology","volume":"13","author":"von Bueren","year":"2011","journal-title":"Neuro Oncol"},{"issue":"26","key":"2024090518440909300_CIT0020","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","article-title":"Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial","volume":"30","author":"Lannering","year":"2012","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024090518440909300_CIT0021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11060-021-03913-5","article-title":"Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: Experience from the German HIT-MED studies","volume":"157","author":"Obrecht","year":"2022","journal-title":"J Neurooncol."},{"issue":"6","key":"2024090518440909300_CIT0022","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"2024090518440909300_CIT0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/neuonc\/nox087","article-title":"Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the response assessment in pediatric neuro-oncology committee","volume":"20","author":"Warren","year":"2018","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024090518440909300_CIT0024","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","article-title":"Response assessment in paediatric high-grade glioma: Recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group","volume":"21","author":"Erker","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"2024090518440909300_CIT0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11060-016-2202-1","article-title":"Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study","volume":"129","author":"Sabel","year":"2016","journal-title":"J Neurooncol."},{"issue":"11","key":"2024090518440909300_CIT0026","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","article-title":"Serial assessment of measurable residual disease in medulloblastoma liquid biopsies","volume":"39","author":"Liu","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"2024090518440909300_CIT0027","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinchem\/hvad115","article-title":"Classification of brain tumors by nanopore sequencing of cell-free DNA from cerebrospinal fluid","volume":"70","author":"Afflerbach","year":"2023","journal-title":"Clin Chem."},{"issue":"19","key":"2024090518440909300_CIT0028","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/onc.2010.599","article-title":"Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation","volume":"30","author":"H\u00e4cker","year":"2011","journal-title":"Oncogene."},{"issue":"12","key":"2024090518440909300_CIT0029","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol Cancer Ther."},{"issue":"9","key":"2024090518440909300_CIT0030","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1158\/1535-7163.MCT-10-0272","article-title":"Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells","volume":"9","author":"Rahman","year":"2010","journal-title":"Mol Cancer Ther."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae071\/57655156\/noae071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/9\/1712\/59028688\/noae071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/9\/1712\/59028688\/noae071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T23:49:54Z","timestamp":1725580194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/9\/1712\/7641402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae071","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"type":"print","value":"1522-8517"},{"type":"electronic","value":"1523-5866"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,5]]}}}